In this week’s edition of InnovationRx, we look at the startup that wants to treat Alzheimer’s with microrobots, medical ...

The family of Henrietta Lacks settles lawsuit with Novartis over use of her cells, marking a turning point in fight for ...

Novartis has settled a suit by Henrietta Lacks' estate alleging the pharmaceutical giant unjustly profited off cells were ...

Guided by immigrant roots, public‑health purpose and a belief in “staying in the ring,” Novartis CEO Vas Narasimhan reflects ...

President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting ...

Ms. Lacks’s family accused Novartis of profiting from her cells, which were taken from her without her consent in 1951, when ...

Novartis, continuing its string of expansions for radioligand therapy manufacturing, announced February 25 that it would ...

So, can Novartis help investors build a millionaire retirement portfolio? Under the right circumstances, yes. The stock can provide stability, reliability, and steady income to a well-diversified ...

The Henrietta Lacks estate has secured a settlement with Novartis over the unauthorized use of her cancer cells, while ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks.

Novartis ( NVS 0.66%) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care, and ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple sclerosis, with a phase 3 readout in relapsing MS expected sometime in the second ...